Kyntra Bio, Inc.
KYNB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000921299
No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Kyntra Bio, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 32 | 1 | 27 | −4 |
| Shares | 1.03M | 26 | 999.0K | −35.7K (−3.5%) |
| Value | $7.01M | $176 | $7.54M | +$527.1K (+7.5%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Kyntra Bio, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 15,697 | $119.0K | 0.01% |
Sold out (5)
Institutions that held Kyntra Bio, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Jane Street Group, LLC | 12,228 | $82.9K |
| ADAR1 Capital Management, LLC | 10,469 | $71.0K |
| CFG Wealth Management Services, Inc. | 3 | $20 |
| US Bancorp | 1 | $7 |
| Citigroup Inc | 1 | $7 |
Not filed for Q2 2026 yet (1)
Institutions that held Kyntra Bio, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 26 | $176 |